ONESOURCE

OneSource Specialty Pharma Share Price

₹1,593.00 -30.7 (-1.89%)

31 Jan, 2025 09:26

SIP TrendupStart SIP in ONESOURCE

Start SIP

Performance

  • Low
  • ₹1,545
  • High
  • ₹1,601
  • 52 Week Low
  • ₹1,466
  • 52 Week High
  • ₹1,800
  • Open Price₹1,601
  • Previous Close₹1,624
  • Volume7,899,685

Investment Returns

  • Over 1 Month -4.61%
  • Over 3 Month -4.61%
  • Over 6 Month -4.61%
  • Over 1 Year -4.61%
SIP Lightning

Smart Investing Starts Here Start SIP with OneSource Specialty Pharma for Steady Growth!

Invest Now

OneSource Specialty Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 18,229
  • P/B Ratio
  • -
  • Average True Range
  • -
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • -
  • MFI
  • -

OneSource Specialty Pharma Financials

OneSource Specialty Pharma Technicals

EMA & SMA

Current Price
₹1,593.00
-30.7 (-1.89%)
pointer
  • stock-down_img
  • Bearish Moving Average 2
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • -
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

1597.23 Pivot Speed
  • R3 1,772.47
  • R2 1,705.23
  • R1 1,664.47
  • S1 1,556.47
  • S2 1,489.23
  • S3 1,448.47

What's your outlook on OneSource Specialty Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

N/A

Group Rank

India’s first specialty pharma CDMO offers drug-device combinations, complex injectables, biologics, and soft gelatin capsules. Operating across multiple technology platforms, its 1,200+ professionals deliver tailored solutions for drug development and manufacturing with agility and expertise.

Onesource Specialty Pharma Ltd has an operating revenue of Rs. 564.48 Cr. on a trailing 12-month basis. An annual revenue growth of 325% is outstanding, Pre-tax margin of -213% needs improvement, ROE of -98% is poor and needs improvement. The company has a debt to equity of 69%, which is bit higher. The stock from a technical standpoint is trading close to its key moving averages, around 2% and 2% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 50 which is POOR indicating the underperformance as compared to other stocks, Group Rank of 23 indicates it belongs to a strong industry group of Medical-Whlsle Drg/Suppl and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

OneSource Specialty Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-29 Quarterly Results

OneSource Specialty Pharma F&O

OneSource Specialty Pharma Shareholding Pattern

37.77%
4.62%
2.47%
17.44%
0%
13.05%
24.65%

About OneSource Specialty Pharma

  • NSE Symbol
  • ONESOURCE
  • BSE Symbol
  • 544292
  • Managing Director
  • Mr. Neeraj Sharma
  • ISIN
  • INE013P01021

Similar Stocks to OneSource Specialty Pharma

OneSource Specialty Pharma FAQs

OneSource Specialty Pharma share price is ₹1,593 As on 31 January, 2025 | 09:12

The Market Cap of OneSource Specialty Pharma is ₹18228.7 Cr As on 31 January, 2025 | 09:12

The P/E ratio of OneSource Specialty Pharma is As on 31 January, 2025 | 09:12

The PB ratio of OneSource Specialty Pharma is As on 31 January, 2025 | 09:12

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23